| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
H2O2-induced cell death is prevented in SH-SY5Y cells by salvigenin (0-100 μM, 3 hours) [1]. In H2O2-exposed SH-SY5Y cells, salvigenin (0-100 μM, 2 hours) dramatically lowers ROS generation, raises glutathione levels, lowers the degree of apoptosis, and enhances autophagy [1].
|
|---|---|
| ln Vivo |
In tumor-bearing mice, salvigenin (0-9.68 μg/mouse/day; intraperitoneal injection; 4 or 12 days) demonstrates immunomodulatory and anti-tumor properties [2].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: SY5Y cells exposed to H2O2 (300 μM) Tested Concentrations: 10, 25, 50 and 100 μM Incubation Duration: 3 hrs (hours) Experimental Results: SH-SY5Y cells (25 and 50μM optimal) protected from H2O2 Protection - Induces cell death. Apoptosis analysis [1] Cell Types: SY5Y cells were exposed to H2O2 (300 μM) Tested Concentrations: 10, 25, 50 and 100 μM Incubation Duration: 2 h Experimental Results: The degree of apoptosis induced by H2O2 was Dramatically diminished. Western Blot Analysis[1] Cell Types: SY5Y cells exposed to H2O2 (300 μM) Tested Concentrations: 10, 25, 50 and 100 μM Incubation Duration: 2 hrs (hours) Experimental Results: diminished cleaved caspase-3 and Bax/Bcl-2 ratio. Reduces caspase-12 and calpain levels. diminished levels of Atg7, Atg12 and LC3-II/LC3-I. |
| Animal Protocol |
Animal/Disease Models: Inbred female balb/c (Bagg ALBino) mouse, 6 to 8 weeks old, containing MCF-7 cells [2]
Doses: 3.65, 5.85, and 9.68 μg/mouse/day for 4 or 12 days Route of Administration: intraperitoneal (ip) injection Experimental Results: demonstrated a significant increase in DTH response in a dose-dependent manner. Dramatically diminished tumor growth rate, increased lymphocyte proliferation index, increased IFN-γ levels and diminished IL-4 production. Spleen CD4+CD25+Foxp3+ T lymphocytes were Dramatically diminished. |
| References | |
| Additional Infomation |
Salvigenin is a trimethoxyflavone that is scutellarein in which the hydroxy groups at positions 4', 6, and 7 are replaced by methoxy groups. It has a role as an autophagy inducer, an apoptosis inhibitor, an antilipemic drug, an immunomodulator, an antineoplastic agent, a neuroprotective agent, a hypoglycemic agent and a plant metabolite. It is a trimethoxyflavone and a monohydroxyflavone. It is functionally related to a scutellarein.
Salvigenin has been reported in Salvia miltiorrhiza, Mesosphaerum urticoides, and other organisms with data available. See also: Tangerine peel (part of). |
| Molecular Formula |
C18H16O6
|
|---|---|
| Molecular Weight |
328.3160
|
| Exact Mass |
328.094
|
| CAS # |
19103-54-9
|
| Related CAS # |
Salvigenin-d9
|
| PubChem CID |
161271
|
| Appearance |
White to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
535.9±50.0 °C at 760 mmHg
|
| Flash Point |
196.9±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
3.01
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
482
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QCDYOIZVELGOLZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O6/c1-21-11-6-4-10(5-7-11)13-8-12(19)16-14(24-13)9-15(22-2)18(23-3)17(16)20/h4-9,20H,1-3H3
|
| Chemical Name |
5-hydroxy-6,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~60.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (6.09 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0458 mL | 15.2290 mL | 30.4581 mL | |
| 5 mM | 0.6092 mL | 3.0458 mL | 6.0916 mL | |
| 10 mM | 0.3046 mL | 1.5229 mL | 3.0458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
